Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy
Phase of Trial: Phase I
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Sunitinib (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 30 Jul 2012 Additional lead trial centre added as reported by ClinicalTrials.gov record.
- 20 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.